Physiologic MR Imaging of Salivary Gland Tumors
PSGT
Physiologic MR Imaging in Distinguishing Benign From Malignant Salivary Gland Tumors
2 other identifiers
interventional
30
1 country
1
Brief Summary
The goal of this study is to use advanced Magnetic Resonance Imaging (MRI) techniques to help identify the difference between cancerous and non-cancerous salivary gland tumors for improving treatment strategies and to aid in the prediction of disease progression.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Aug 2020
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 25, 2020
CompletedFirst Posted
Study publicly available on registry
June 30, 2020
CompletedStudy Start
First participant enrolled
August 25, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2026
September 9, 2025
September 1, 2025
5.8 years
June 25, 2020
September 7, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Differentiation and Progression Free
Differentiation of malignant from benign neoplasms and progression free survival at 6 month starting from end of chemo-radiation treatment
6 Month after the end of treatment
Study Arms (1)
Salivary Gland Tumor
OTHERInterventions
You are being asked to complete one research MRI scan with and without contrast since your most recent clinical evaluation and/or prior imaging has shown the presence of a suspicious salivary gland tumor, prior to your scheduled upcoming surgery. MRI contrast agents act like a dye to make MRI pictures brighter and easier to read. During each MRI scan, you will have an intravenous line (IV line) placed. The IV line allows the contrast agent to be injected into your vein. If you have a history of renal disease you may be asked to complete a blood draw of approximately 2.5cc (½ teaspoon), for glomerular filtration rate (GFR) assessment for participation into the study.
Eligibility Criteria
You may qualify if:
- Possess a salivary gland lesion of 1cm3 size
- Have no prior history of treatment for salivary gland lesion
You may not qualify if:
- Has any prior history of cancer other than SGT
- Has any MRI contra-indications
- Has a history of known renal disease.
- Has history of prior radiation to head and neck region
- Is pregnant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Abramson Cancer Center at Penn Medicinelead
- McCabe Fundcollaborator
Study Sites (1)
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sanjeev Chawla
Professor
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Research Professor of Radiology
Study Record Dates
First Submitted
June 25, 2020
First Posted
June 30, 2020
Study Start
August 25, 2020
Primary Completion (Estimated)
June 1, 2026
Study Completion (Estimated)
June 1, 2026
Last Updated
September 9, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share